Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Argatroban in thrombotic stroke.

Marian P LaMonte1

  • 1Division of Emergency Medicine, University of Maryland School of Medicine, The Maryland Brain Attack Center, Baltimore, MD 21201, USA. mlamonte@umm.edu

Pathophysiology of Haemostasis and Thrombosis
|June 18, 2003
PubMed
Summary

Direct thrombin inhibitors show promise for acute stroke treatment. A Japanese study found argatroban safe and effective in reducing neurological impairment after ischemic stroke when given within 48 hours.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke: The Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) Collaboration.

JAMA neurology·2023
Same author

Racial Disparity in Mechanical Thrombectomy Utilization: Multicenter Registry Results From 2016 to 2020.

Journal of the American Heart Association·2022
Same author

Ceribell EEG shortens seizure diagnosis and workforce time and is useful for COVID isolation.

Epilepsia open·2021
Same author

Patient Characteristics and Outcomes Associated with Decline in Stroke Volumes During the Early COVID-19 Pandemic.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2021
Same author

Diagnosing deep cerebral venous thrombosis.

Proceedings (Baylor University. Medical Center)·2018
Same author

A regional system of stroke care provides thrombolytic outcomes comparable with the NINDS stroke trial.

Annals of emergency medicine·2008

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Acute stroke presents a significant unmet medical need.
  • Thrombin plays a critical role in thrombotic processes relevant to ischemic stroke.
  • Direct thrombin inhibition offers a potential therapeutic strategy.

Purpose of the Study:

  • To review evidence for direct thrombin inhibition in acute stroke.
  • To explore the mechanism of action, including microthrombi reduction and improved cerebral blood flow.
  • To present findings from a clinical study on argatroban in ischemic stroke.

Main Methods:

  • Literature review of direct thrombin inhibitors for stroke.
  • Analysis of proposed mechanisms of action.
  • Evaluation of a clinical trial involving argatroban administration post-stroke onset.

Main Results:

  • Direct thrombin inhibition is proposed to reduce secondary microthrombi.
  • Improved regional collateral cerebral blood flow is a potential benefit.
  • Argatroban, administered within 48 hours, demonstrated safety and efficacy in reducing neurological impairment in a Japanese study.

Conclusions:

  • Direct thrombin inhibition is a viable therapeutic approach for acute ischemic stroke.
  • Argatroban shows potential as a treatment for reducing stroke-related neurological deficits.
  • Further clinical studies are warranted to confirm these findings and explore broader applications.

Related Experiment Videos